Haseki Tıp Bülteni (Apr 2018)

The Effects of Smoking on Metabolic Syndrome and Aterogenic Index of Plasma: A Case-Control Study

  • Ruhuşen Kutlu,
  • Ahmet Öksüz

DOI
https://doi.org/10.4274/haseki.03511
Journal volume & issue
Vol. 56, no. 1
pp. 50 – 57

Abstract

Read online

Aim: Smoking is an important risk factor for various health problems, especially cancer, heart and lung diseases. atherogenic index of plasma (AIP) reflects the coronary atherosclerosis/cardiovascular risk. This study was conducted to evaluate the effects of smoking cigarette on metabolic syndrome and AIP. Methods: In this case-control study, records of 1110 patients aged 18 years and older were retrospectively evaluated. Files of 900 eligible patients were examined (900/1110). Metabolic syndrome was diagnosed according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria. AIP was calculated using a calculator. Results: The mean age of the subjects was 36.02±11.72 years. 51.2% (n=461) were women, 72.6% (n=653) were married, 35.6% (n=320) were university graduate, 32.0% (n=288) were civil servants, and 53.6% (n=482) were smoking. The frequency of metabolic syndrome was 26.4% (n=238). There was no statistically significant difference between metabolic syndrome and smoking status (p>0.05). There was a statistically significant relationship between AIP and smoking status (p<0.001). AIP was found to be statistically higher in patients with metabolic syndrome (p<0.001). Conclusion: Smoking is a serious risk factor for atherosclerosis and cardiovascular disease. In our study, AIP was found to be significantly higher in smokers than in non-smokers. However, there was no statistically significant difference between metabolic syndrome and smoking status.

Keywords